Compound 7

(2Z,2'E)-Dimethyl 2,2'-((3S,7R,11S,12S,15S,17R,21R,23R,25S,E)-25-acetoxy-1,11,21-trihydroxy-17-(hydroxymethyl)-10,10,26,26-tetramethyl-12-(octanoyloxy)-19-oxo-18,27,28,29-tetraoxatetracyclo[21.3.1.13,7.111,15]nonacos-8-ene-5,13-diylidene)diacetate

From: Designed, synthetically accessible bryostatin analogues potently induce activation of latent HIV reservoirs in vitro

View in PubChem | MDL Molfile | ChemDraw

InChIKey RKXUHIOQDOWAQJ-RUFXTULGSA-N

Synthetic procedure: See article for the definitive version of this procedure and for full experimental details.

In a polypropylene vial, the enoate mixture 28 (ca. 0.0045 mmol) was dissolved in THF (2.0 mL). The resulting solution was cooled in an ice water bath and HF·pyridine (70% HF, 500 μL) was added dropwise over 30 s. The mixture was stirred at 0 °C for 5 min and was then warmed to ambient temperature. After 74 h, the reaction was quenched by its dropwise addition to stirred, saturated aqueous NaHCO3 (20 mL). This mixture was extracted with EtOAc (3 × 20 mL) and the combined organic phase was washed with 30 mL 0.2 N HCl. The acidic aqueous phase was extracted with additional EtOAc (2 × 20 mL). The combined organic phase was dried over Na2SO4, filtered, and concentrated to afford a crude residue that was used immediately in the following step. The crude residue from the previous step was dissolved in a solution of PPTS (0.05 M in 20% H2O:THF, 600 μL, 0.03 mmol) at ambient temperature. After 39 h, the reaction was then diluted with Et2O (500 μL), H2O (500 μL), and brine (500 μL). The organic an aqueous phases were separated, and the aqueous phase was extracted with Et2O (5 × 1 mL). The combined organic layer was dried over MgSO4, filtered, and concentrated to afford a crude residue that was partially purified by flash chromatography (60% EtOAc in hexanes) to afford a mixture of enoate analogues that was separated by reverse phase HPLC (C18, 10 micron, 10 × 250 mm, 65 → 100 % MeCN in H2O) to afford 1.3 mg Z-enoate analogue 7 (29% over 3 steps) and 1.2 mg E-enoate analogue S7 (27% over 3 steps) as amorphous white solids. Compound purity was established by TLC (one spot) and 1H-NMR analysis. 1H NMR (CDCl3, 500 MHz): δ = 5.98 (d, 1H, J = 1.8 Hz, C34), 5.74 (d, 1H, J = 15.7 Hz, C17), 5.68 (bs, 1H, C30), 5.32 (m, 1H, C25), 5.32 (dd, 1H, J = 8.4, 15.7 Hz), 5.16 (s, 1H, C19-OH), 5.14 (m, 1H, C7), 5.13 (s, 1H, C20), 4.24 (d, 1H, J = 12.0 Hz, C3-OH), 4.23 (m, 1H, C5), 4.17 (m, 1H, C3), 4.04 (tt, 1H, J = 2.2, 11.3 Hz, C23), 3.98 (ddd, 1H, J = 2.3, 8.6, 11.1 Hz, C15), 3.84 (m, 1H, C26), 3.78 (m, 1H, C13), 3.72-3.61 (m, 3H, C14, C22, C26), 3.70 (s, 3H, -CO2Me), 3.68 (s, 3H, -CO2Me), 2.52-2.42 (m, 3H, C2, C2, C19-OH), 2.31 (m, 2H, C40, C40), 2.21 (m, 1H, C12), 2.14-1.96 (m, 6H, C4, C10, C12, C22, C24, C26-OH), 2.05 (s, 3H, C7-OAc), 1.91 (m, 1H, C14), 1.78 (m, 2H, C6, C24), 1.67 (d, 1H, J = 15.4 Hz, C10), 1.64-1.53 (m, 3H, C4, C41, C41), 1.48 (q, 1H, J = 12.0 Hz, C6), 1.27 (m, 8H, C42-C45), 1.15 (s, 3H, -CH3), 1.00 (s, 6H, -CH3, -CH3), 0.95 (s, 3H, -CH3), 0.87 (t, 3H, J = 7.1 Hz, C46) ppm. 13C NMR (CDCl3, 100 MHz): δ = 172.5, 172.4, 171.1, 167.1, 166.8, 156.5, 151.9, 139.1, 129.7, 119.9, 114.6, 102.0, 99.0, 79.3, 74.4, 73.0, 71.7, 71.6, 68.5, 65.9, 65.6, 64.8, 51.3, 51.2, 45.0, 44.2, 42.4, 42.1, 41.1, 39.8, 36.4, 35.9, 34.8, 33.4, 31.8, 31.2, 29.2, 29.0, 24.8, 24.7, 22.7, 21.3, 21.2, 19.9, 17.0, 14.2 ppm. IR: 3466, 3350, 2930, 1738, 1722, 1715, 1660, 1435, 1408, 1366, 1247, 1157, 1079, 1030, 1003, 984, 859, 811 cm−1. HRMS (TOF MS ES+): Calculated for C46H70O17Na+: 917.4505; Found: 917.4523. [α]D23.2 = + 42.6 ± 1.1° (c = 0.23, CH2Cl2). Rf = 0.29 (50% EtOAc in petroleum ether), one purple spot, p-anisaldehyde stain.